HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

The Wegovy injection query is usually a question about dosing format: is there a pill version, is there an injection version, what are the practical differences, and what does the FDA-approved market look like as of April 2026? This article reports the format reality factually, explains the bioavailability trade-offs, and covers what PlexusDx offers in each format through its Weight Management Protocols.

What formats of Wegovy exist as of April 2026

Wegovy (semaglutide 2.4 mg) is available only as a once-weekly subcutaneous injection as of April 2026 — there is no oral Wegovy product. The oral formulation of semaglutide, Rybelsus (also Novo Nordisk), is marketed for type 2 diabetes, not chronic weight management. PlexusDx offers Semaglutide Injection and Semaglutide Oral as separate protocols under its Weight Management Protocols.

How oral and injection formats compare

Injectable GLP-1 receptor agonists deliver predictable bioavailability and are typically dosed once weekly (or once daily in the case of liraglutide). Oral GLP-1 receptor agonists must survive gastric digestion — Rybelsus uses an absorption enhancer (SNAC) to achieve systemic absorption and requires strict fasting administration. Real-world adherence depends on patient preference, injection tolerance, administration-timing requirements, and lifestyle. Head-to-head efficacy data between oral and injectable semaglutide in chronic weight management is limited; oral semaglutide is labeled for type 2 diabetes, not weight management.

Dosing schedules

Injectable semaglutide is titrated per product label from 0.25 mg weekly through higher doses (Ozempic up to 2 mg, Wegovy up to 2.4 mg). Injectable tirzepatide is titrated per product label from 2.5 mg weekly through higher doses (Mounjaro and Zepbound up to 15 mg). Rybelsus (oral semaglutide) starts at 3 mg daily and titrates to 7 or 14 mg daily. No dosing direction here substitutes for your prescribing provider's guidance.

Cost and access considerations

Oral and injection formats are priced separately, carry different insurance coverage rules, and may have different eligibility for manufacturer savings programs. PlexusDx Weight Management Protocols publish per-protocol pricing on the relevant product pages.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: Coupons for Wegovy, Wegovy Discount.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology underneath every decision. Take the Precision Peptide Genetic Test, or explore the protocol directly.

Frequently Asked Questions

Is there an oral version of Wegovy?

As of April 2026, Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 receptor agonist, and it is labeled for type 2 diabetes — not weight management. There is no FDA-approved oral tirzepatide. PlexusDx offers separate oral semaglutide and tirzepatide protocols through its Weight Management Protocols.

How does the oral form compare with the injection form?

Injection forms deliver predictable bioavailability with once-weekly dosing. Oral semaglutide uses an absorption enhancer and requires strict fasting administration per the label. Head-to-head weight-management efficacy data between the two formats is limited; oral semaglutide is FDA-approved for type 2 diabetes, not chronic weight management.

Is the injection form right for me?

Format choice depends on individual preference, injection tolerance, administration-timing ability, insurance coverage, and goals of therapy. Your prescribing provider weighs these factors alongside the FDA-approved indication on your prescription, your medical history, concurrent medications, and side-effect considerations. PlexusDx provides both injection and oral options through its Weight Management Protocols.

Does genetic testing predict response to one format over another?

No. The Precision Peptide Genetic Test does not predict response to any specific compound or format. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies regardless of whether the compound is delivered orally or by injection.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education